Latest Articles and Analysis

Stagnant CMS reimbursement rates since 2016 threaten addiction treatment provider closures and service access.

COVID-19 disrupts STI surveillance as staff redeployment, testing shortages, and clinic closures create gaps.

Calls for restoring Obama-era guidance defining 340B patient protections and enforcement mechanisms.

Study of 109,283 patients links HIV status and viral hepatitis coinfection to significantly increased liver cancer rates.

Examines CMS's rebate rule on copay accumulator programs that block patient assistance from counting toward deductibles.

Restrictive Medicaid policies limit HCV treatment access through fibrosis restrictions and sobriety requirements.

Broken advocacy pipeline lacks investment in leadership development, compensation, and mentorship.

Explores technology innovations in HIV care including mobile apps and drone pharmacy delivery.

UNAIDS report highlights HIV-HCV coinfection rates among people who inject drugs globally and in the US.

Supreme Court allows states to ration hepatitis C care in prisons, setting dangerous precedent for incarcerated people.

Reviews Biden's first 100 days on healthcare: infrastructure, subsidies, harm reduction, and health equity.

Quarterly update on HCV treatment coverage across ADAPs, Medicaid, Veterans programs, and patient assistance options.

Analysis of Kanawha County HIV outbreak highlighting substance use, rural healthcare gaps, and pandemic impact.

Housing instability increases HIV/HCV acquisition by 55-65%; housing investments outpace health interventions.

COVID-19 vaccination priority for people with HIV and chronic liver disease amid immunological risks.

Merck-Gilead partnership on long-acting injectables Islatravir and Lenacapavir for HIV treatment.

Assesses pandemic's ongoing impact on HIV, HCV, and SUD surveillance and care with vaccine rollout.

COVID-19 vaccine development spurs reflection on 35-year HIV vaccine search and mRNA technology advances.

Arizona's restrictive Medicaid formulary limits single-tablet HIV regimens and HCV agents post-expansion.

NASTAD's hepatitis C navigation toolkit uses peer navigators and wraparound services for people who use drugs.